US equities
|
INTC
$64.56
▼-29.87%
AMZN
$238.23
▼-2.28%
NVDA
$203.76
▼-4.63%
MU
$878.90
▼-5.93%
SNDK
$1,159.39
▼-12.83%
GOOGL
$279.29
▼-1.60%
AMD
$500.48
▼-11.64%
SPCX
$137.08
▼-4.73%
INTC
$64.56
▼-29.87%
AMZN
$238.23
▼-2.28%
NVDA
$203.76
▼-4.63%
MU
$878.90
▼-5.93%
SNDK
$1,159.39
▼-12.83%
GOOGL
$279.29
▼-1.60%
AMD
$500.48
▼-11.64%
SPCX
$137.08
▼-4.73%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Aardvark Therapeutics, Inc. - Common Stock
(NQ:
AARD
)
1.380
-0.060 (-4.17%)
Delayed Quote
Updated: 12:53 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aardvark Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); and GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law
October 06, 2026
From
Grabar Law Office
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th
October 05, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
If You Lost Money Investing in Aardvark Therapeutics, Inc. (AARD) Contact Robbins LLP for Information About Recovering Your Losses
October 05, 2026
San Diego, California--(Newsfile Corp. - October 5, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class...
Via
Newsfile
Topics
Initial Public Offering
Lawsuit
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
October 05, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Important Notice to Long-Term Shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL); Ardelyx, Inc. (NASDAQ: ARDX); Aardvark Therapeutics, Inc. (NASDAQ: AARD); and GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI): Grabar Law Office is Investigating
October 05, 2026
From
Grabar Law Office
Via
GlobeNewswire
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
AARDVARK DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD
October 02, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
AARD Shareholder Alert: Aardvark Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
October 02, 2026
From
Levi & Korsinsky, LLP
Via
ACCESS Newswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
October 01, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th
September 30, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Deadline
September 30, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
September 29, 2026
From
Pomerantz LLP
Via
GlobeNewswire
AARDVARK DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD
September 28, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
September 28, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
September 24, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aardvark Therapeutics, Inc. (AARD)
September 24, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
September 22, 2026
From
Pomerantz LLP
Via
GlobeNewswire
AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Deadline
September 22, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is
September 22, 2026
From
Grabar Law Office
Via
GlobeNewswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
September 21, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Aardvark Therapeutics, Inc. (NASDAQ: AARD) for Potential Violations of the Federal Securities Laws
September 18, 2026
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
AARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
September 18, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
September 18, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Robbins LLP is Investigating Allegations that Aardvark Therapeutics, Inc. Misled Investors Regarding the Viability and Efficacy of its Lead Drug Candidate ARD-101
September 17, 2026
San Diego, California--(Newsfile Corp. - September 17, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class...
Via
Newsfile
Topics
Initial Public Offering
Lawsuit
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aardvark Therapeutics, Inc. (AARD)
September 17, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); Erasca, Inc. (NASDAQ: ERAS); and Hub Group, Inc. (NASDAQ: HUBG): Grabar Law Office is Investigating Claims on Your Behalf
September 16, 2026
From
Grabar Law Office
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role
September 15, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
September 15, 2026
From
Pomerantz LLP
Via
GlobeNewswire
AARDVARK DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD
September 15, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
September 15, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
